Mallinckrodt Sees FY15 Adj. EPS Of $6.70 - $7.20 - Quick Facts

(RTTNews) - Mallinckrodt plc (MNK), a global specialty biopharmaceutical company, issued forecast for its fiscal year ending September 25, 2015, expecting adjusted earnings per share in the range of $6.70 - $7.20, reflecting a weighted average, diluted share count of around 118 million. The non-GAAP effective tax is likely to range between 20% and 23%. Capital expenditures are targeted to be in the range of $130 million - $150 million.

For fiscal 2015, net sales are projected to be in the range of $3.65 billion - $3.75 billion on an operational basis, excluding the impact of fluctuations in foreign currency exchange rates. Analysts polled by Thomson-Reuters estimated the company's annual earnings to be $6.80 per share, on $3.78 billion in revenue. Analysts' estimates typically exclude one-time items.

Net sales for the company's Specialty Pharmaceutical unit are expected to be in the range of $2.87 billion - $2.92 billion. This outlook includes full-year net sales contributions from H.P. Acthar Gel and OFIRMEV, two leading branded products in its Specialty Pharmaceuticals segment. Net sales for the company's Global Medical Imaging segment are expected to be in the range of $760 million - $800 million.